CROs offering Ligand-Binding Bioanalysis (Large Molecule) with mRNA
8 published
8 published CROs match Ligand-Binding Bioanalysis (Large Molecule) and mRNA.
Locations in this set include United States, China, India, 30 countries, 30+ countries, and Belgium.
Capabilities that show up most often in this set: Bioanalysis, Biomarker Assays, LC-MS Bioanalysis (Small Molecule), Immunogenicity Assays (ADA / NAb), and Translational Research.
Matching companies
Amador BioscienceAmador Bioscience provides bioanalysis and biomarker services, including LCMS, immunoassays, flow cytometry, and immunogenicity testing, alongside clinical pharmacology modeling and regulatory affairs support. Its labs are GLP compliant, and its teams work across the US, China, and Europe.
Aragen Life SciencesGlobal CRDMO partner offering integrated discovery-to-commercialization services across small molecules and biologics, with 4000+ scientists and R&D/manufacturing campuses in Asia, North America, and Europe.
Avance BiosciencesAvance Biosciences is a CRO and contract testing organization offering CGMP- and GLP-compliant analytical and bioanalytical services for drug development. Services cover preclinical and clinical studies, CMC support, CLIA testing, and assay development.
CertaraCertara transforms drug development with proprietary biosimulation software, predictive modeling, and AI-driven services spanning discovery through commercialization. Serving 2,400+ biopharmaceutical companies and regulatory agencies across 70 countries, Certara's model-informed drug development (MIDD) platform accelerates clinical and regulatory decision-making.
PharmaronPremier life science CRO and CDMO offering integrated R&D and manufacturing across drug discovery, preclinical, clinical development, and commercialization for small molecules, biologics, and cell & gene therapies. 25,000+ employees across China, US, and UK.
SoCal Biosciences, Inc.San Diego-based bioanalytical CRO specializing in assay development and analysis for mRNA, oligonucleotides, and large molecules across discovery through clinical development phases.
Syngene InternationalInnovation-led CRDMO offering integrated scientific services from early discovery through commercial manufacturing, with cGMP-compliant facilities, 5,200+ scientists, and a new 50,000-liter single-use bioreactor capacity in the U.S.
WuXi AppTecGlobal CRDMO platform providing integrated end-to-end contract research, development, and manufacturing services across discovery, preclinical, clinical, and commercial phases for small molecules, peptides, oligonucleotides, and biologics across 30+ countries.
Markdown mirror: /explore/ligand-binding-bioanalysis/mrna.md